Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome

F.B. Vincent, M. Bubicich, Sarah Downie-Doyle, Fabienne Mackay-Fisson, Eric F. Morand, Maureen Rischmueller

Research output: Contribution to journalLetterResearchpeer-review

Original languageEnglish
Number of pages3
JournalClinical and Experimental Rheumatology
Publication statusAccepted/In press - 2019

Cite this

@article{c94034b477af417fab4485a2b735204f,
title = "Serum soluble Fas and Fas ligand (FasL) in primary Sj{\"o}gren’s syndrome",
author = "F.B. Vincent and M. Bubicich and Sarah Downie-Doyle and Fabienne Mackay-Fisson and Morand, {Eric F.} and Maureen Rischmueller",
year = "2019",
language = "English",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",

}

Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome. / Vincent, F.B.; Bubicich, M.; Downie-Doyle, Sarah ; Mackay-Fisson, Fabienne; Morand, Eric F.; Rischmueller, Maureen.

In: Clinical and Experimental Rheumatology, 2019.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome

AU - Vincent, F.B.

AU - Bubicich, M.

AU - Downie-Doyle, Sarah

AU - Mackay-Fisson, Fabienne

AU - Morand, Eric F.

AU - Rischmueller, Maureen

PY - 2019

Y1 - 2019

M3 - Letter

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

ER -